577 related articles for article (PubMed ID: 21075600)
1. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
[TBL] [Abstract][Full Text] [Related]
2. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
[TBL] [Abstract][Full Text] [Related]
3. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.
Georgiades A; Davis VG; Atkins AS; Khan A; Walker TW; Loebel A; Haig G; Hilt DC; Dunayevich E; Umbricht D; Sand M; Keefe RSE
Schizophr Res; 2017 Dec; 190():172-179. PubMed ID: 28433500
[TBL] [Abstract][Full Text] [Related]
4. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
5. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
[TBL] [Abstract][Full Text] [Related]
6. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension.
Harvey PD; Siu CO; Hsu J; Cucchiaro J; Maruff P; Loebel A
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1373-82. PubMed ID: 24035633
[TBL] [Abstract][Full Text] [Related]
7. Calibration and cross-validation of MCCB and CogState in schizophrenia.
Lees J; Applegate E; Emsley R; Lewis S; Michalopoulou P; Collier T; Lopez-Lopez C; Kapur S; Pandina GJ; Drake RJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3873-82. PubMed ID: 26018529
[TBL] [Abstract][Full Text] [Related]
8. Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia.
Fervaha G; Hill C; Agid O; Takeuchi H; Foussias G; Siddiqui I; Kern RS; Remington G
Schizophr Res; 2015 Aug; 166(1-3):304-9. PubMed ID: 26004693
[TBL] [Abstract][Full Text] [Related]
9. The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.
Fonseca AO; Berberian AA; de Meneses-Gaya C; Gadelha A; Vicente MO; Nuechterlein KH; Bressan RA; Lacerda ALT
Schizophr Res; 2017 Jul; 185():148-153. PubMed ID: 28110814
[TBL] [Abstract][Full Text] [Related]
10. An empirical evaluation of the MATRICS Consensus Cognitive Battery in bipolar disorder.
Van Rheenen TE; Rossell SL
Bipolar Disord; 2014 May; 16(3):318-25. PubMed ID: 24119238
[TBL] [Abstract][Full Text] [Related]
11. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
[TBL] [Abstract][Full Text] [Related]
12. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
14. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia.
Burton CZ; Vella L; Harvey PD; Patterson TL; Heaton RK; Twamley EW
Schizophr Res; 2013 May; 146(1-3):244-8. PubMed ID: 23507359
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.
Silverstein SM; Jaeger J; Donovan-Lepore AM; Wilkniss SM; Savitz A; Malinovsky I; Hawthorne D; Raines S; Carson S; Marcello S; Zukin SR; Furlong S; Dent G
J Clin Exp Neuropsychol; 2010 Nov; 32(9):937-52. PubMed ID: 20455131
[TBL] [Abstract][Full Text] [Related]
16. A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS).
Hurford IM; Ventura J; Marder SR; Reise SP; Bilder RM
Schizophr Res; 2018 May; 195():327-333. PubMed ID: 28918221
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
Citrome L; Cucchiaro J; Sarma K; Phillips D; Silva R; Tsuchiya S; Loebel A
Int Clin Psychopharmacol; 2012 May; 27(3):165-76. PubMed ID: 22395527
[TBL] [Abstract][Full Text] [Related]
18. The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China.
Shi C; Kang L; Yao S; Ma Y; Li T; Liang Y; Cheng Z; Xu Y; Shi J; Xu X; Zhang C; Franklin DR; Heaton RK; Jin H; Yu X
Schizophr Res; 2015 Dec; 169(1-3):109-115. PubMed ID: 26441005
[TBL] [Abstract][Full Text] [Related]
19. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
20. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
Rodriguez-Jimenez R; Bagney A; Garcia-Navarro C; Aparicio AI; Lopez-Anton R; Moreno-Ortega M; Jimenez-Arriero MA; Santos JL; Lobo A; Kern RS; Green MF; Nuechterlein KH; Palomo T
Schizophr Res; 2012 Feb; 134(2-3):279-84. PubMed ID: 22192501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
